-
ESMO China Strong Voice The research of Professor Han Baohui / Professor Lu Shun was featured in the ESMO oral presentation
Time of Update: 2022-11-01
At this year's ESMO conference, Professor Han Baohui orally reported the results of a phase II randomized controlled study: the results of a preliminary interim analysis of sindilimab + anlotinib in patients with treatment-naïve metastatic NSCLC.
-
Notice of change of the 25th National Clinical Oncology Congress and 2022 CSCO Annual Conference
Time of Update: 2022-11-01
In order to effectively prevent and control the epidemic and ensure the quality of the academic annual meeting, the CSCO Council leaders urgently discussed and decided:In view of the current domestic new crown epidemic prevention and control situation and the latest requirements at all levels, the Xiamen Municipal Government notified on September 9 to suspend various large-scale conferences before November 1.
-
Professor Chen Yu: Attacking poison with poison, oncolytic virus combination therapy is expected to revolutionize the treatment pattern of melanoma
Time of Update: 2022-11-01
Coinciding with the perfect conclusion of the European Society of Oncology (ESMO) Annual Conference, the "research on oncolytic virus (recombinant human adenovirus type 5) combined with programmed cell death protein-1 (PD-1) monoclonal antibody in the treatment of advanced melanoma patients who have failed previous immunotherapy" was unveiled on the international stage in the form of e-Poster.
-
The latest schedule framework of the 25th National Clinical Oncology Congress and 2022 CSCO Annual Conference
Time of Update: 2022-11-01
The 25th National Clinical Oncology Congress and 2022 CSCO Annual Conference, co-hosted by the Chinese Society of Clinical Oncology and Beijing Xisco Clinical Oncology Research Foundation, will be held from November 5 to 12, 2022 in the form of "CSCO Annual Meeting Academic Week".
-
Patients with chronic myeloid leukemia can achieve treatment-free remission after first-line treatment with nilotinib: 10-year follow-up results of the GIMEMA CML 0307 study announced
Time of Update: 2022-11-01
Poke "Read Original" to see more01ResearchmethodsmethodsThe GIMEMA CML working group initiated a phase II study (NCT00481052) with nilotinib as first-line therapy in 2007, and between June 2007 and February 2008, 73 adults (≥ 18 years) patients newly diagnosed with CP-CML were enrolled in 18 centers in Italy.
-
The peak circuit turns, the clouds are cleared| mCRC patients are failing in the first- and second-line standard treatment, and the third-line precision treatment is turning things around
Time of Update: 2022-11-01
F* is only for medical professionals to read and refer to mCRC chemotherapy is not sensitive, progressing layer by layer, and see how third-line treatment can break through the dilemmaIn recent years,
-
The retrosigmoid sinus approach uses the posterior condylar catheter as an anatomical marker of craniotomy
Time of Update: 2022-11-01
Conclusion of the study Finally, the authors point out that the posterior condylar catheter vein (PCEV) is a simple, intuitive, safe, and effective intraoperative anatomical marker; Neurosurgeons can extend soft tissue separation and bony exposure into the foramen magnum, which increases visibility and operability of the CPA region.
-
Who is more accurate for preoperative risk assessment of rectal cancer, MRI or NICE guidelines?
Time of Update: 2022-11-01
For medical professionals only to read and refer to see what Professor Gu Jin's team at Peking University Shougang Hospital said that the screening of patients for preoperative treatment of rectal can
-
Express targeted STAT3 for the treatment of hepatocellular carcinoma, and the innovative therapy was fast-track designated by the FDA
Time of Update: 2022-11-01
▲If you have any business needs, please long press to scan the QR code above, or▎WuXi AppTec content team editorTvardi Therapeutics today announced that its oral small molecule STAT3 inhibitor TTI-101 has received Fast Track designation from the U.
-
Latest data: Memory NK cell therapy can overcome TME, and is expected to overcome a variety of NK-resistant solid tumors
Time of Update: 2022-11-01
544px;white-space: normal;background-color: rgb(255, 255, 255);text-align: center;box-sizing: border-box !important;overflow-wrap: break-word !important;margin-bottom: 0px;">October 24, 2022 /eMedClub News/--Recently, immunology company INmuneBio presented its preclinical data of memory NK cell therapy INKmune, which showed that INKmune can convert patients' normal resting NK (rNK) cells into effective memory-like NK cells.
-
Professor Zheng Qianqian: The data of 2022 ESMO platinib for the treatment of RET mutant thyroid cancer have been updated again to continue to write a longer survival
Time of Update: 2022-11-01
Table 3 mPFS and mOS update results for ITT population Fig. 3 PFS results of RET mutant MTC population Pratinib has a strong and sustained remission in the treatment of RET fusion thyroid cancer, providing a new option for patients refractory to iodine In this update, the cohort of patients with RET fusion TC expanded from 21 to 25, and the population baseline was similar to the past.
-
JCO: Bevacizumab in combination with radiation therapy improves the prognosis of patients with recurrent glioblastoma
Time of Update: 2022-11-01
(If you need the original text, you can add Xiaobian WeChat yxj_oncology to obtain) Scan the QR code above to get more cutting-edge information1J Clin Oncol: Bevacizumab plus reradiation therapy improves outcomes in patients with recurrent glioblastoma▎Clinical questions: Compared with bevacizumab alone, Whether bevacizumab plus reradiation improves overall survival (OS) and/or progression-free survival (PFS) in patients with recurrent glioblastoma (GBM) is unclear.
-
ESMO field directly tackles the therapeutic potential of TIL therapy in melanoma
Time of Update: 2022-11-01
TIL is a reclusing cell therapy with a response rate (ORR) of 36-70% in patients with advanced melanoma observed in multiple phase 1/2 trials.
TIL is a reclusing cell therapy with a response rate (ORR) of 36-70% in patients with advanced melanoma observed in multiple phase 1/2 trials.
-
【2022 ESMO】The prospect of recombinant human vascular endostatin combined with immunological first-line treatment of non-small cell lung cancer is promising
Time of Update: 2022-11-01
On September 9~13, 2022, the Congress of the European Society of Medical Oncology (ESMO) was held simultaneously online and offline in Paris, France. As Europe's prestigious and influential oncology c
-
Differences between neurofibromatosis types 1 and 2
Time of Update: 2022-11-01
Research results NF1 is the most common and is considered a diagnostic feature with major clinical manifestations including café au lait spots, axillary or inguinal freckles, neurofibroma or plexiform neurofibromas, optic gliomas, Lisch nodules, and bone lesions such as sphenoid dysplasia.
-
European Radiology: Deep learning enables 3D MRCPs for IPMN patients to be "more selective, more exciting"
Time of Update: 2022-10-31
Recently, a study published in the journal European Radiology compared the difference between acquisition time and image quality obtained by IPMN patients using various techniques, and further clarified the clinical practical value of DLR, providing technical support for clinical accurate IPMN diagnosis and follow-up evaluation.
-
Clin Cancer Res: nivolumab in combination with temozolomide for neuroendocrine tumors
Time of Update: 2022-10-31
This is a non-randomized, multi-cohort, single-center Phase 2 trial that enrolled patients with advanced NEN and relapsed/metastatic small cell lung cancer to be treated with nivolumab (480 mg/4 weeks) plus temozolomide (150 mg/m2 orally, days 1-5/28) until disease progression or intolerable toxicity.
-
Wonderful collection of Healthy China 2030-2022 inter-hospital exchange conference on standardized diagnosis and treatment of bowel cancer
Time of Update: 2022-10-31
In 2016, the Central Committee of the Communist Party of China and the State Council issued the "Healthy China 2030" Planning Outline, which clearly stated that It is required that the 5-year survival
-
European Radiology: Are all local progressions of liver cancer related to thermal ablation?
Time of Update: 2022-10-31
However, many studies have shown that recurrence-free survival after thermal ablation is lower than surgical resection, and that the incidence of local tumor progression (LTP) after ablation is higher (15-20%) than surgical treatment (5-10%).
-
EJNMMI: A strong combination of low-dose radionuclides and PD-L1/CTLA-4 dual targeted immunosuppressant KN046 improves immunotherapy response rate
Time of Update: 2022-10-31
As a PD-L1/CTLA-4 Fc fusion bispecific antibody, KN046 has significant advantages in anti-tumor efficacyStudies have reported that low-dose ionizing radiation stimulation can be used for immune enhancement by inducing the release of tumor immunogenicity-associated antigens.
